Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Xencor settled a commercial dispute with Alexion regarding U.S. royalties for Ultomiris, agreeing to a $105 million payment to be made in two equal installments starting in August 2026. Under the agreement, Alexion will cease paying U.S. royalties on the drug, while Xencor retains its rights to royalties on ex-U.S.
Key figures
- Payment 1
- $52.5 million
- Payment 2
- $52.5 million
- Cash runway
- through 2028
- Settlement amount
- $105 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.